- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
The first clinical trial for antibody cocktail REGN-COV2 has been announced in a press release today. The study will measure the efficacy of both treatment and prevention of COVID-19. Four populations will be studied including: high risk people with no infection, uninfected people who have had close exposure to a COVID-19 patient, hospitalised and non-hospitalised patients infected with COVID-19.
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
